Literature DB >> 23860772

Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil.

Bhushan J Toley1, Zachary G Tropeano Lovatt, Josephine L Harrington, Neil S Forbes.   

Abstract

Intratumoral transport and binding are important mechanisms that determine the efficacy of cancer drugs. Current drug screening methods rely heavily on monolayers of cancer cells, which overlook the contribution of tissue-level transport and binding. To quantify these factors, we developed a method that couples an in vitro, drug-delivery device containing a three-dimensional cell mass and a mathematical model of drug diffusion, binding to DNA, release from carriers, and clearance. Spheroids derived from LS174T human colon carcinoma cells were inserted into rectangular chambers to form rectangular cell masses (tissue) and subjected to continuous medium perfusion. To simulate drug delivery and clearance, the tissues were treated with doxorubicin followed by drug-free medium. To evaluate the effect of liposome encapsulation, tissues were treated with liposome-encapsulated doxorubicin (Doxil). Spatiotemporal dynamics of drug distribution and apoptosis was measured by fluorescence microscopy. The diffusivity and DNA binding constant of doxorubicin were determined by fitting experimental data to the mathematical model. Results show that an ideal combination of diffusivity, binding constant, clearance rate, and cytotoxicity contribute to the high therapeutic efficacy of doxorubicin. There was no detectable release of doxorubicin from Doxil in the tissues. The rate of doxorubicin release, evaluated by fitting experimental data to the mathematical model, was below therapeutically effective levels. These results show that despite enhanced systemic circulation obtained by liposome encapsulation, the therapeutic effect of Doxil is limited by slow intratumoral drug release. The experimental and computational methods developed here to calculate drug efficacy provide mechanisms to explain poor performance of drug candidates, and enable design of more successful cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860772      PMCID: PMC3760710          DOI: 10.1039/c3ib40021b

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  52 in total

1.  Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.

Authors:  N Seetharamu; E Kim; H Hochster; F Martin; F Muggia
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

Review 2.  Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.

Authors:  J Gabrielsson; A R Green
Journal:  J Pharmacol Exp Ther       Date:  2009-09-24       Impact factor: 4.030

Review 3.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.

Authors:  B Meibohm; H Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  1997-10       Impact factor: 1.366

4.  Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation.

Authors:  G Helmlinger; F Yuan; M Dellian; R K Jain
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

5.  Interference of daunomycin with metabolic events of the cell cycle in synchronized cultures of rat fibroblasts.

Authors:  R Silvestrini; A Di Marco; T Dasdia
Journal:  Cancer Res       Date:  1970-04       Impact factor: 12.701

Review 6.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

7.  Flux analysis shows that hypoxia-inducible-factor-1-alpha minimally affects intracellular metabolism in tumor spheroids.

Authors:  Byoung-jin Kim; Neil S Forbes
Journal:  Biotechnol Bioeng       Date:  2007-04-15       Impact factor: 4.530

Review 8.  Tissue transport of anti-cancer drugs.

Authors:  Jan Lankelma
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

9.  In vitro and in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages.

Authors:  A Mantovani
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

10.  [Biological activity of adriamycin in vitro].

Authors:  R Silvestrini; C Gambarucci; T Dasdia
Journal:  Tumori       Date:  1970 May-Jun
View more
  12 in total

1.  Intra-tumoral drug concentration mapping within solid tumor micro-milieu using in-vitro model and doxorubicin as a model drug.

Authors:  Ahmed M Al-Abd; Alaa Khedr; Salah G Atteiah; Fahad A Al-Abbasi
Journal:  Saudi Pharm J       Date:  2020-05-11       Impact factor: 4.330

Review 2.  In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.

Authors:  Altug Ozcelikkale; Hye-Ran Moon; Michael Linnes; Bumsoo Han
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-14

3.  Engineered bacteria detect spatial profiles in glucose concentration within solid tumor cell masses.

Authors:  Jan T Panteli; Neil S Forbes
Journal:  Biotechnol Bioeng       Date:  2016-09-20       Impact factor: 4.530

4.  Trg-deficient Salmonella colonize quiescent tumor regions by exclusively penetrating or proliferating.

Authors:  Miaomin Zhang; Neil S Forbes
Journal:  J Control Release       Date:  2014-12-15       Impact factor: 9.776

5.  Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model.

Authors:  Altug Ozcelikkale; Kyeonggon Shin; Victoria Noe-Kim; Bennett D Elzey; Zizheng Dong; Jian-Ting Zhang; Kwangmeyung Kim; Ick Chan Kwon; Kinam Park; Bumsoo Han
Journal:  J Control Release       Date:  2017-09-20       Impact factor: 9.776

6.  Fabrication of Doxorubicin-Loaded Lipid-Based Nanocarriers by Microfluidic Rapid Mixing.

Authors:  Chia-Ying Lee; Tsuimin Tsai; Po-Chun Peng; Chin-Tin Chen
Journal:  Biomedicines       Date:  2022-05-27

7.  Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors.

Authors:  Greg M Thurber; Thomas Reiner; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  Mol Cancer Ther       Date:  2014-02-19       Impact factor: 6.261

8.  Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response.

Authors:  Tudor Petreus; Elaine Cadogan; Gareth Hughes; Aaron Smith; Venkatesh Pilla Reddy; Alan Lau; Mark James O'Connor; Susan Critchlow; Marianne Ashford; Lenka Oplustil O'Connor
Journal:  Commun Biol       Date:  2021-08-24

9.  The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella.

Authors:  Vishnu Raman; Nele Van Dessel; Owen M O'Connor; Neil S Forbes
Journal:  J Immunother Cancer       Date:  2019-02-12       Impact factor: 13.751

10.  Characterising a PDMS based 3D cell culturing microfluidic platform for screening chemotherapeutic drug cytotoxic activity.

Authors:  M Ibrahim Khot; Mark A Levenstein; Greg N de Boer; Gemma Armstrong; Thomas Maisey; Hafdis S Svavarsdottir; Helen Andrew; Sarah L Perry; Nikil Kapur; David G Jayne
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.